

UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST
BOARD OF DIRECTORS
THURSDAY 25 JANUARY 2018

Title:	QUARTER 3 BOARD ASSURANCE FRAMEWORK
Responsible Director:	David Burbridge, Director of Corporate Affairs
Contact:	Berit Reglar, Deputy Foundation Secretary

Purpose:	To provide the Board with the high level risks within the context of the Board Assurance Framework (BAF).
-----------------	---

Confidentiality Level & Reason:	None
--	------

Medium Term Plan Ref:	Annual Plan
------------------------------	-------------

Key Issues Summary:	<p>The BAF has been reviewed by the Executive team in conjunction with their Executive Risk Registers and any relevant divisional/corporate risk registers. Any historical data have been archived if superseded/no longer pertinent. Track changes have been used in the Appendix to assist the Board in the identification of any changes to the BAF. Key updates include:</p> <ul style="list-style-type: none"> • Finance: <ul style="list-style-type: none"> ○ The Trust is on track to deliver agreed surplus dependant on a range of factors. • Operational Performance: <ul style="list-style-type: none"> ○ Norman Power step down facility is now open. Red - Green has been rolled out across all areas. KPI remains in place for discharges before 1pm. ○ The Newton Seamless surgery programme continues; the aim of the programme is to improve productivity within theatres. • Timely/effective transfer of care to other provides: <ul style="list-style-type: none"> ○ The findings of the Newton diagnostic were presented to the STP Board in January 2018. A new model for care in crisis will be presented to the STP Board in February 2018 for approval with an allocated rescue plant work programme identified. • Strategic Workforce: <ul style="list-style-type: none"> ○ A meeting was held with HEFT to look at the formulation of a combined workforce plan and identification of key workforce risks and current mitigation plans. A further meeting will be held to review work around workforce data and mitigation plans. • Adherence to regulatory requirements and national guidance: <ul style="list-style-type: none"> ○ By the end of Q3 2017/18 the clinical compliance
----------------------------	---

	<p>framework has been implemented for all agreed specialities. An escalation process for non-compliance was agreed at the DCA Governance Group in November 2017.</p> <ul style="list-style-type: none"> ○ Work continues to see how the Trust can collect data in the format required for the CQC's annual provider information request. ● Failure to reduce the transmission of infection: <ul style="list-style-type: none"> ○ During Q3 5 outbreaks of C. difficile infection were reported. There has been a slight reduction in the use of piperacillin/tazobactam. ● UK exit from EU may have an adverse impact on the Trust: <ul style="list-style-type: none"> ○ The Government has issued a technical note on citizen's rights which seeks to clarify aspects of its proposal for EU citizens' rights post Brexit. Affected staff holding Permanent Residence status will be able to exchange their status to Settled Status. For those not holding Permanent Resident status, the proposal is for application for Settles Status to be mandatory. Affected staff who are not yet able to evidence the five years' continuous residence necessary to obtain settled status, but who can evidence that they were resident before the specified date, will be given temporary status. This will enable them to remain in the UK until they have built up five years' continuous residence, allowing them to apply for settled status. ● Risk to the Trust of the transaction involving HEFT not obtaining regulatory approval: <ul style="list-style-type: none"> ○ A meeting will be help between Department of Health, NHSI, NHSE to discuss transaction red lines on 23.01.2018.
<p>Recommendations:</p>	<p>The Board is asked to:</p> <ol style="list-style-type: none"> 1. Review the revised BAF and identify any gaps in controls or assurance; and 2. Consider the newly added risks and confirm appropriate risk owners.
<p>Signed: David Burbridge</p>	<p>Date: January 2018</p>